Reviewing ImmuCell Corporation (ICCC)’s and Acorda Therapeutics Inc. (NASDAQ:ACOR)’s results – MS Wkly

As Biotechnology companies, ImmuCell Corporation (NASDAQ:ICCC) and Acorda Therapeutics Inc. (NASDAQ:ACOR) are our subject to compare. And more specifically their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Table 1 demonstrates ImmuCell Corporation and Acorda Therapeutics Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 has ImmuCell Corporation and Acorda Therapeutics Inc.s return on assets, return on equity and net margins.

Volatility and Risk

A 1.15 beta means ImmuCell Corporations volatility is 15.00% more than S&P 500s volatility. From a competition point of view, Acorda Therapeutics Inc. has a 1.1 beta which is 10.00% more volatile compared to S&P 500.

Liquidity

The current Quick Ratio of ImmuCell Corporation is 6.3 while its Current Ratio is 7.3. Meanwhile, Acorda Therapeutics Inc. has a Current Ratio of 4.3 while its Quick Ratio is 4. ImmuCell Corporation is better positioned to pay off its short-term and long-term debts than Acorda Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for ImmuCell Corporation and Acorda Therapeutics Inc. can be find in next table.

Meanwhile, Acorda Therapeutics Inc.s average price target is $6.67, while its potential upside is 148.88%.

Institutional & Insider Ownership

The shares of both ImmuCell Corporation and Acorda Therapeutics Inc. are owned by institutional investors at 23.1% and 0% respectively. About 0.1% of ImmuCell Corporations share are held by insiders. Competitively, insiders own roughly 1.5% of Acorda Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year ImmuCell Corporation has stronger performance than Acorda Therapeutics Inc.

Summary

Acorda Therapeutics Inc. beats ImmuCell Corporation on 6 of the 11 factors.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Here is the original post:
Reviewing ImmuCell Corporation (ICCC)'s and Acorda Therapeutics Inc. (NASDAQ:ACOR)'s results - MS Wkly